2
|
Muntañola A, Mirás F, Hernández‐Rivas JA, Baile M, Osorio S, Terol MJ, Gimeno E, Alonso R, Baltasar P, López‐García A, Labrador J, López‐Jiménez J, Hernández‐Rodríguez I, Alfayate A, Oliveira AC, Gómez‐Roncero MI, Vidal MJ, Bárez A, López‐Rubio M, Riaza R, Correa J, Hernández‐Sánchez E, Romero P, Yáñez L, Andreu R, Santiago R, Zabalza A, Torres A, Seri C, Ramírez‐Payer A, García‐Malo MD, García‐Pintos M, Mateos Mazón JJ, Rodríguez‐Fernández A, Ma Vale A, Ríos E, Loscertales J, Do Nascimiento J, Pérez‐Fernández I, José Lis M, Pérez S, Ruiz ME, Villalón L, Velasquez CA, Campoy F, Muiña B, Soler JA, Sánchez MJ, Cuesta A, Pimentel A, Sánchez‐Ramírez M, Ruiz‐Camps I, Villacampa G, Bosch F, Abrisqueta P. IMPACT OF DISEASE TREATMENT ON THE OUTCOME OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH COVID‐19: A MULTICENTER STUDY ON BEHALF OF GELLC. Hematol Oncol 2021. [PMCID: PMC8426866 DOI: 10.1002/hon.53_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
3
|
Muntañola A, Villacampa G, Hernández-Rivas JÁ, Alonso R, Mirás F, Osorio S, Baile M, Baltasar P, López Jiménez J, Hernandez-Rodriguez I, Valenciano S, Alfayate A, Gimeno E, Bárez A, Oliveira AC, Riaza R, Romero P, Delgado J, Yáñez L, Zabalza A, Torres A, Gómez-Roncero MI, Crespo M, Córdoba R, Mateos-Mazón JJ, Pérez S, Andreu R, Labrador J, Ruiz ME, Velasquez CA, Terol MJ, Santiago R, Vidal MJ, Campoy García F, Villalón L, Muiña BS, Soler JA, Seri C, Sánchez MJ, Cuesta A, Ramos R, Sánchez-Montalvá A, Ruiz-Camps I, González M, Abrisqueta P, Bosch F. Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country. Exp Hematol Oncol 2020; 9:37. [PMID: 33339537 PMCID: PMC7746919 DOI: 10.1186/s40164-020-00195-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Accepted: 12/07/2020] [Indexed: 01/21/2023] Open
Affiliation(s)
- Ana Muntañola
- Hospital Universitari Mútua Terrassa, Barcelona, Spain
| | - Guillermo Villacampa
- Oncology Data Science, Vall D'Hebron Institute of Oncology, Barcelona, Spain.,SOLTI Breast Cancer Research Group, Barcelona, Spain
| | | | | | - Fátima Mirás
- Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Santiago Osorio
- Hospital Universitario Gregorio Marañón/Gregorio Marañón Health Institute (IiSGM), Madrid, Spain
| | - Mónica Baile
- Hospital Universitario de Salamanca/IBSAL, CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain
| | | | | | | | | | | | | | | | - Ana C Oliveira
- Hospital Duran i Reynals-ICO Hospitalet, Barcelona, Spain
| | | | - Pilar Romero
- Hospital Universitario Donostia, San Sebastián, Spain
| | | | - Lucrecia Yáñez
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | | | - Ana Torres
- Complejo Asistencial de Segovia, Segovia, Spain
| | | | - Marta Crespo
- Department of Hematology, Vall d'Hebron Barcelona Hospital Campus, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain
| | - Raúl Córdoba
- Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | | | - Sonia Pérez
- Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | - Rafael Andreu
- Hospital Universitario La Fe de Valencia, Valencia, Spain
| | | | | | | | - Mª José Terol
- Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - Raquel Santiago
- Hospital Sant Joan de Déu de Manresa - Fundació ALTHAIA, Barcelona, Spain
| | | | | | - Lucía Villalón
- Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | | | - Joan Alfons Soler
- Consorci Corporació Sanitària Parc Taulí de Sabadell, Barcelona, Spain
| | - Cristina Seri
- Hospital Central de la Defensa Gómez Ulla, Madrid, Spain
| | | | - Amalia Cuesta
- Hospital Sierrallana (Torrelavega), Cantabria, Spain
| | - Rafael Ramos
- Hospital Universitario de Badajoz, Badajoz, Spain
| | - Adrián Sánchez-Montalvá
- Department of Hematology, Vall d'Hebron Barcelona Hospital Campus, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain
| | - Isabel Ruiz-Camps
- Department of Hematology, Vall d'Hebron Barcelona Hospital Campus, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain
| | - Marcos González
- Hospital Universitario de Salamanca/IBSAL, CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain
| | - Pau Abrisqueta
- Department of Hematology, Vall d'Hebron Barcelona Hospital Campus, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
| | - Francesc Bosch
- Department of Hematology, Vall d'Hebron Barcelona Hospital Campus, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain
| | | |
Collapse
|
4
|
Herishanu Y, Shaulov A, Fineman R, Bašić‐Kinda S, Aviv A, Wasik‐Szczepanek E, Jaksic O, Zdrenghea M, Greenbaum U, Mandac I, Simkovic M, Morawska M, Benjamini O, Spacek M, Nemets A, Bairey O, Trentin L, Ruchlemer R, Laurenti L, Stanca Ciocan O, Doubek M, Shvidel L, Dali N, Mirás F, De Meûter A, Dimou M, Mauro FR, Coscia M, Bumbea H, Szász R, Tadmor T, Gutwein O, Gentile M, Scarfò L, Tedeschi A, Sportoletti P, Gimeno Vázquez E, Marquet J, Assouline S, Papaioannou M, Braester A, Levato L, Gregor M, Rigolin GM, Loscertales J, Medina Perez A, Nijziel MR, Popov VM, Collado R, Slavutsky I, Itchaki G, Ringelstein S, Goldschmidt N, Perry C, Levi S, Polliack A, Ghia P. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. Am J Hematol 2020; 95:604-611. [PMID: 32096887 DOI: 10.1002/ajh.25766] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2020] [Revised: 02/19/2020] [Accepted: 02/20/2020] [Indexed: 12/14/2022]
Abstract
In recent years, considerable progress has been made in frontline therapy for elderly/physically unfit patients with CLL. The combination of obinutuzumab and chlorambucil (O-Clb) has been shown to prolong progression free survival (PFS, median PFS-31.5 months) and overall survival (OS) compared to chlorambucil alone. More recently, obinutuzumab given in combination with either ibrutinib or venetoclax improved PFS but not OS when compared to O-Clb. In this retrospective multinational, multicenter co-operative study, we evaluated the efficacy and safety of frontline treatment with O ± Clb in unfit patients with CLL, in a "real-world" setting. Patients with documented del (17p13.1)/TP53 mutation were excluded. A total of 437 patients (median age, 75.9 years; median CIRS score, 8; median creatinine clearance, 61.1 mL/min) were included. The clinical overall response rate was 80.3% (clinical complete and partial responses in 38.7% and 41.6% of patients, respectively). Median observation time was 14.1 months and estimated median PFS was 27.6 months (95% CI, 24.2-31.0). In a multivariate analysis, high-risk disease [del (11q22.3) and/or IGHV-unmutated], lymph nodes of diameter > 5 cm, obinutuzumab monotherapy and reduced cumulative dose of obinutuzumab, were all independently associated with shorter PFS. The median OS has not yet been reached and estimated 2-year OS is 88%. In conclusion, in a "real-world" setting, frontline treatment with O-Clb achieves PFS comparable to that reported in clinical trials. Inferior outcomes were noted in patients with del (11q22.3) and/or unmutated IGHV and those treated with obinutuzumab-monotherapy. Thus, O-Clb can be still considered as legitimate frontline therapy for unfit CLL patients with low-risk disease.
Collapse
Affiliation(s)
- Yair Herishanu
- Department of HematologyTel Aviv Sourasky Medical Center Tel Aviv Israel
- Sackler Faculty of MedicineTel Aviv University Tel‐Aviv Israel
| | - Adir Shaulov
- Hadassah Hebrew University Medical Center Jerusalem Israel
| | - Riva Fineman
- Department of HematologyRambam Health Care Campus Haifa Israel
| | | | - Ariel Aviv
- Department of HematologyHaEmek Medical Center Afula Israel
- Faculty of MedicineTechnion Israel Institute of Technology Haifa Israel
| | - Ewa Wasik‐Szczepanek
- Department of Hematooncologyand Bone Marrow Transplantation Medical University Lublin Poland
| | | | - Mihnea Zdrenghea
- Iuliu Hatieganu University of Medicine and Pharmacy Cluj‐Napoca Romania
| | - Uri Greenbaum
- Ben‐Gurion University, Soroka University Medical Center Beer Sheva Israel
| | | | - Martin Simkovic
- University Hospital and Medical School Hradec Kralove Hradec Kralove Czech Republic
| | | | - Ohad Benjamini
- Sackler Faculty of MedicineTel Aviv University Tel‐Aviv Israel
- Hematology DivisionChaim Sheba Medical Center Ramat Gan Israel
| | - Martin Spacek
- Charles University and General Hospital in Prague Prague Czech Republic
| | | | - Osnat Bairey
- Rabin Medical Center, Beilinson Hospital; Sackler Faculty of MedicineTel Aviv University Tel Aviv Israel
| | | | - Rosa Ruchlemer
- Department of HematologyShaare Zedek Medical Center Jerusalem Israel
| | - Luca Laurenti
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
| | | | - Michael Doubek
- Department of Internal Medicine‐Hematology and OncologyMedical Faculty of Masaryk University and University Hospital Brno Brno Czech Republic
| | - Lev Shvidel
- Department of HematologyKaplan Medical Center Rehovot Israel
- Hebrew University of Jerusalem Jerusalem Israel
| | | | | | | | - Maria Dimou
- Hematology Section ‐ 1st Department Of Propaedeutic Internal MedicineLaikon Hospital Athens Greece
| | - Francesca R. Mauro
- Hematology, Department of Translational and Precision MedicineSapienza University, Policlinico Umberto I Rome Italy
| | - Marta Coscia
- Department of Molecular Biotechnology and Health SciencesUniversity of Torino Torino Italy
| | - Horia Bumbea
- Emergency University Clinical Hospital Bucharest Romania
| | - Róbert Szász
- Division of Hematology, Department of Internal Medicine, Faculty of MedicineUniversity of Debrecen Debrecen Hungary
| | | | | | - Massimo Gentile
- Hematology Unit and Biotechnology Research Unit, A.O. of Cosenza Cosenza Italy
| | - Lydia Scarfò
- Division of Experimental OncologyIRCCS Ospedale San Raffaele Milan Italy
- Università Vita‐Salute San Raffaele Milan Italy
| | - Alessandra Tedeschi
- Department of Haematology, Niguarda Cancer CenterASST Grande Ospedale Metropolitano Niguarda Milan Italy
| | - Paolo Sportoletti
- Institute of Hematology and Center for Hemato‐Oncological Research, Ospedale S. Maria della Misericordia, University of Perugia Perugia Italy
| | | | - Juan Marquet
- Hematology and HemotherapyHospital Universitario Ramón y Cajal Madrid Spain
| | - Sarit Assouline
- Division of HematologyJewish General Hospital, Montreal Quebec Canada
| | - Maria Papaioannou
- First Department of Internal Medicine, Division of HaematologyAHEPA University Hospital, Aristotle University of Thessaloniki Thessaloniki Greece
| | | | - Luciano Levato
- Department Hematology‐OncologyAzienda Ospedaliera Pugliese‐Ciaccio Catanzaro Italy
| | - Michael Gregor
- Division of HematologyCantonal Hospital of Lucerne Lucerne Switzerland
| | - Gian M. Rigolin
- Hematology Section, Department of Medical SciencesUniversity of Ferrara‐Azienda Ospedaliera‐Universitaria di Ferrara, University of Ferrara Ferrara Italy
| | | | | | | | | | | | | | - Gilad Itchaki
- Rabin Medical Center, Beilinson Hospital; Sackler Faculty of MedicineTel Aviv University Tel Aviv Israel
| | | | | | - Chava Perry
- Department of HematologyTel Aviv Sourasky Medical Center Tel Aviv Israel
- Sackler Faculty of MedicineTel Aviv University Tel‐Aviv Israel
| | - Shai Levi
- Department of HematologyTel Aviv Sourasky Medical Center Tel Aviv Israel
| | - Aaron Polliack
- Hadassah Hebrew University Medical Center Jerusalem Israel
| | - Paolo Ghia
- Division of Experimental OncologyIRCCS Ospedale San Raffaele Milan Italy
- Università Vita‐Salute San Raffaele Milan Italy
| |
Collapse
|